Our goal and the focus are to leverage our gene regulation technology to maximize value.To achieve this goal, we are pursuing a two-pronged strategy.

• Develop therapeutic topical products for humans and animals.Upon successful completion of Phase I/II of clinical trials, the company intends to seek distribution agreements with domestic and foreign pharmaceutical companies.These agreements will fund the remaining clinical trials and FDA marketing approval steps.
• Generate revenue by providing Drug Target Validation services while seeking and forming product development partnerships with pharmaceutical and biotechnology companies.

This patented technology represents a significant breakthrough in intra- cellular gene regulation; and our topical preparations will present a high safety/efficacy profile.We have significant laboratory data that supports this posture.

For this reason, we are pursuing product opportunities meeting these criteria:

• Diseases and disorders of the skin and others amenable to topical formulation drug delivery through body orifices (ocular, nasal, vaginal and anal) and,
• Diseases for which current drugs and those in late trials are not very effective and,
• Diseases with high incidence rates, a large world market and a growing unmet need.

Published laboratory (in vitro) studies have shown very clearly that the Company's gene regulation technology is very effective in reducing protein expression in target cells.These scientific results have led to the execution of a product development strategy directed to skin diseases and conditions based on topical delivery.